Claims
- 1. A compound of the formula ##STR3## wherein X.sup.1 and X.sup.2 are halo;
- R is lower alkyl of from 1 to 6 carbon atoms;
- R.sup.1 is lower alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, lowercycloalkylloweralkyl of 4 to 7 carbon atoms and phenyl;
- R.sup.2 is hydrogen or lower alkyl of 1 to 6 carbon atoms, and carboxy lower alkyl of 2 to 6 carbon atoms; and the pharmaceutically acceptable salts thereof.
- 2. A compound according to claim 1 wherein X.sup.1 and X.sup.2 are chloro.
- 3. A compound according to claim 2 wherein R is cyclopentyl.
- 4. A compound according to claim 3 wherein R.sup.2 is H.
- 5. A compound according to claim 4 wherein R.sup.1 is methyl, that is 4-[(6,7-dichloro-2-cyclopentyl-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanoic acid.
- 6. A compound according to claim 5 which is the (+) enantiomer.
- 7. A compound according to claim 4 wherein R.sup.1 is ethyl, that is, 4-[(6,7-dichloro-2-cyclopentyl-2-ethyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic acid.
- 8. A compound according to claim 4 wherein R.sup.1 is propyl, that is, 4-[(6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-2-propyl-1H-inden-5-yl)oxy]butanoic acid.
- 9. A compound according to claim 4 wherein R.sup.1 is butyl, that is, 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic acid.
- 10. A compound according to claim 9 which is the (+) enantiomer.
- 11. A compound according to claim 9 which is the (-) enantiomer.
- 12. A compound according to claim 3 wherein R.sup.1 is methyl and R.sup.2 is 1-carboxy-1-methylethyl, that is, 1-carboxy-1-methylethyl (+) 4-[(6,7-dichloro-2-cyclopentyl-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]butanoate.
- 13. A compound according to claim 4 wherein R.sup. is butyl and R.sup.2 is 1-carboxy-1-methylethyl, that is, 1-carboxy-1-methylethyl (+) 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoate.
- 14. A compound according to claim 4 wherein R.sup.1 is butyl and R.sup.2 is 1-carboxy-1-methylethyl, that is, (-) 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoate.
- 15. A method of treating persons with gray matter edema which comprises administering to such a person an effctive amount of a compound of the formulae: ##STR4## where X.sup.1 and X.sup.2 are halo;
- R is lower alkyl of from 1 to 6 carbon atoms;
- R.sup.1 is lower alkyl of 1-4 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, lowercycloalkylloweralkyl of 4 to 7 carbon atoms and phenyl;
- R.sup.2 is hydrogen or lower alkyl, and carboxy lower alkyl of 2 to 6 carbon atoms; or the pharmaceutically acceptable salts thereof.
- 16. The method of claim 15 wherein X.sup.1 and X.sup.2 are chloro.
- 17. The method of claim 16 where R.sup.2 is hydrogen.
- 18. The method of claim 17 where R is cyclopentyl.
- 19. The method of claim 18 where R.sup.1 is lower alkyl.
- 20. The method of claim 19 where R.sup.1 is methyl.
- 21. The method of claim 20 where the compound is the (+) enantiomer.
- 22. The method of claim 19 where R is ethyl.
- 23. The method of claim 19 where R.sup.1 is propyl.
- 24. The method of claim 19 where R.sup.1 is butyl.
- 25. The method of claim 24 where the compound is the (+) enantiomer.
- 26. The method of claim 24 where the compound is the (-) enantiomer.
- 27. The method of claim 16 where R is cyclopentyl, R.sup.1 is methyl and R.sup.2 is 1-carboxy-1-methylethyl.
- 28. The method of claim 27 where the compound is the (+) enantiomer.
- 29. The method of claim 16 where R is cyclopentyl, R.sup.1 is butyl and R.sup.2 is 1-carboxy-1-methylethyl.
- 30. The method of claim 29 where the compound is the (-) enantiomer.
- 31. The method of claim 29 where the compound is the (+) enantiomer.
- 32. A composition for treating gray matter edema which comprises a carrier and an effective amount of the formula: ##STR5## where X.sup.1 and X.sup.2 are halo;
- R is lower alkyl of from 1 to 6 carbon atoms;
- R.sup.1 is lower alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, lowercycloalkylloweralkyl of 4 to 7 carbon atoms and phenyl;
- R.sup.2 is hydrogen or lower alkyl, and carboxy lower alkyl of 2 to 6 carbon atoms;
- or the pharmaceutically acceptable salts thereof.
Parent Case Info
This is a continuation of application Ser. No. 291,982, filed Aug. 11, 1982, which in turn is a continuation-in-part of application Ser. No. 183,546, filed Sept. 2, 1980, both which have been abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4070539 |
Cragoe, Jr. |
Jan 1928 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
291982 |
Aug 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
183546 |
Sep 1980 |
|